Ezetimibe/rosuvastatin - Alvogen Korea

Drug Profile

Ezetimibe/rosuvastatin - Alvogen Korea

Alternative Names: DP R207; Rosuvastatin/ezetimibe - Alvogen Korea

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DreamPharma Corporation
  • Developer Alvogen Korea
  • Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Propanols; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercholesterolaemia

Most Recent Events

  • 01 Mar 2015 DreamPharma Corporation completes the phase III ROSE trial in Hypercholesterolaemia in South Korea (NCT02445352)
  • 01 Jul 2014 Phase-III clinical trials in Hypercholesterolaemia in South Korea (PO) (NCT02445352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top